Metformin for PCOS: What It Does, and What to Ask Before You Start

What metformin actually does

Metformin lowers the amount of glucose your liver releases and makes your muscle and fat tissue respond better to the insulin you already make. It does not push your pancreas to produce more insulin, which is why metformin taken on its own does not usually cause hypoglycaemia.

That matters for PCOS because high circulating insulin is one of the drivers of ovarian androgen production. Bring insulin down and you remove some of the pressure on that pathway. This is the whole mechanism, and it is worth knowing because it tells you which parts of PCOS metformin can plausibly touch — and which it cannot.

You may now see the condition written as polyendocrine metabolic ovarian syndrome (PMOS), after a 2026 global consensus of more than 50 organisations renamed it. Only the name moved. Every metformin trial described below still applies, and nothing about how the drug is prescribed changed. If the new label is new to you, PCOS is now PMOS covers what did and did not change.

What the trials actually found

The 2023 international guideline was informed by a systematic review and meta-analysis of randomised trials comparing metformin, with or without lifestyle change, against placebo in PCOS. Here is what it measured, alongside the reproductive outcomes from a 2019 Cochrane review of 41 trials in 4,552 women.

Outcome	Average difference vs placebo	Certainty	Source
BMI	−0.53 kg/m² (95% CI −0.95 to −0.12)	Moderate	Melin 2023
HOMA-IR (insulin resistance)	−0.50 (95% CI −0.91 to −0.09)	Moderate	Melin 2023
Fasting glucose	−0.13 mmol/L, about 2 mg/dL	Moderate	Melin 2023
LDL cholesterol	−0.16 mmol/L, about 6 mg/dL	Low	Melin 2023
Triglycerides	−0.11 mmol/L, about 10 mg/dL	Low	Melin 2023
Ovulation	OR 2.64 (95% CI 1.85 to 3.75)	Low	Sharpe 2019
Clinical pregnancy	OR 1.98 (95% CI 1.47 to 2.65)	Moderate	Sharpe 2019
Live birth	OR 1.59 (95% CI 1.00 to 2.51); 19% on placebo, 19–37% on metformin	Low	Sharpe 2019
Gastrointestinal side effects	OR 4.00 (95% CI 2.63 to 6.09); 10% on placebo, 22–40% on metformin	Moderate	Sharpe 2019

Read the BMI row carefully, because it is the one most often oversold. Half a point of BMI is roughly 1.5 kg on a 170 cm frame. Metformin is a metabolic drug that sometimes shifts weight a little; it is not a weight-loss treatment, and no one should start it expecting one.

The insulin-resistance and lipid rows are where the more consistent signal sits. If you want the background on why that marker matters, insulin resistance and PCOS sets out what HOMA-IR is measuring.

Metformin and fertility: the honest version

Metformin improves ovulation rates. Improving ovulation is not the same as improving live births, and the trials separate cleanly on this point.

In a randomised trial of 626 women with PCOS, live-birth rates were 22.5% with clomiphene, 7.2% with metformin alone, and 26.8% with both. Metformin alone came third by a wide margin. Adding metformin to clomiphene did not clearly beat clomiphene by itself, and the Cochrane review reached the same uncertain verdict on that combination while confirming that gastrointestinal side effects roughly quadruple when the two are combined.

The 2023 international guideline names letrozole, not metformin, as the first-line drug for ovulation induction in PCOS.

One genuine subgroup finding: when metformin was compared head to head with clomiphene, results split by body size. Women in the higher-BMI trials did worse on metformin, while the non-obese trials leaned the other way. The Cochrane authors rated this evidence very low quality and drew no conclusion from it — but it is the reason a prescriber may weigh metformin differently depending on your starting point.

Side effects, and the two that matter most

Gastrointestinal upset is the common one. Nausea, cramping, and diarrhoea appear in a substantial minority — the meta-analysis put the odds of mild gastrointestinal effects at roughly seven times placebo. It is usually worst in the first weeks and dose-related, which is why prescribers typically start low, increase slowly, take it with food, and sometimes switch to the extended-release formulation. That is a conversation to have before you give up on the drug, not after.

Vitamin B12 falls with long-term use. In the Diabetes Prevention Program Outcomes Study, participants taking metformin 850 mg twice daily had low or borderline-low B12 in 19.1% of cases at five years versus 9.5% on placebo, and each additional year of use raised the odds of deficiency by 13%. The authors recommended routine B12 testing for people on long-term metformin. Ask whether yours is being checked.

Lactic acidosis is the fear, and it is very rare. Pooled data across 347 trials and cohort studies found no cases in 70,490 patient-years of metformin use, and a JAMA systematic review put the overall incidence at roughly 3 to 10 cases per 100,000 person-years — indistinguishable from the background rate. The precautions below exist to keep it that way, not because the risk is high.

What the dose decision actually depends on

There is no standard PCOS dose to look up, and this article is not going to give you one. What a prescriber is weighing looks like this.

Input	Why it changes the decision	What to ask
Kidney function (eGFR)	Metformin is cleared by the kidneys; reduced function means dose reduction or stopping	“What was my eGFR, and how often will you recheck it?”
Why you are taking it	Metabolic markers, cycle regularity and ovulation induction are different goals with different review points	“Which outcome are we treating, and what would tell us it is working?”
Gut tolerance	Titration speed and immediate- vs extended-release are chosen around this	“If the nausea is bad, do we slow the increase or change formulation?”
Other medicines	Some drugs compete for the same kidney transporters; insulin or sulfonylureas raise hypoglycaemia risk	“Does anything on my list interact with this?”
Pregnancy plans	Whether metformin continues, stops, or is combined with an ovulation agent changes entirely	“If I conceive, do I stop or continue?”
Scans and surgery	Metformin is often paused around iodinated contrast imaging and some procedures	“Do I hold it before a CT with contrast?”

Who should not take it

Metformin is restricted or paused in several situations, all of them listed on the prescribing information for every metformin product: significantly reduced kidney function, acute illness with vomiting or dehydration, severe liver disease, decompensated heart failure, conditions causing low oxygen, and heavy alcohol use. The JAMA review found that metformin remains reasonable in mild to moderate kidney impairment with dose adjustment and monitoring — but that is a prescriber’s call made against your actual eGFR, not a general rule.

If you are already taking another glucose-lowering medicine, a GLP-1 medication, or diuretics, that list needs to go in front of whoever writes the prescription.

Metformin versus inositol, and other comparisons people ask about

Metformin is a licensed medicine with decades of safety data and a regulator behind it. Inositol is a supplement. They are not the same category of thing, and this site will never rank a supplement above a prescribed medication. If you are weighing options, that comparison belongs in the appointment, not in a search result — and the rest of the supplements and medications section is written on that assumption.

Your next step

Write down three things before your next appointment: your most recent eGFR and B12 if you have them, every medicine and supplement you take, and the one outcome you most want to change — cycles, metabolic markers, or trying to conceive. Those three inputs are what turn a vague “should I be on metformin?” into a decision your prescriber can actually make with you.

Not sure which PCOS pattern you are working with? Take the quiz first — it changes what you should be asking for.